Menu
Back to Journals » Psoriasis: Targets and Therapy » Volume 15
ISSN: 2230-326X
- View all (178)
- Volume 15, 2025 (22)
- Volume 14, 2024 (23)
- Volume 13, 2023 (7)
- Volume 12, 2022 (22)
- Volume 11, 2021 (14)
- Volume 10, 2020 (8)
- Volume 9, 2019 (13)
- Volume 8, 2018 (12)
- Volume 7, 2017 (9)
- Volume 6, 2016 (15)
- Volume 5, 2015 (13)
- Volume 4, 2014 (5)
- Volume 3, 2013 (4)
- Volume 2, 2012 (10)
- Volume 1, 2011 (1)
Archive: Volume 15, 2025
Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study
Mrowietz U, Sommer R, Gerdes S, Reguiai Z, Weger W, Daudén E, Maul JT, Ghislain PD, Laws PM, Naldi L, De Jong E, Mburu S, Koscielny V, Massana E, Domenech A, Gaarn du Jardin K, Kasujee I, Augustin M
Psoriasis: Targets and Therapy 2025, 15:243-259
Published Date: 28 June 2025
Effectiveness and Safety of Adalimumab Biosimilars in Pediatric Psoriasis: A Multi-Center International Experience
Bertoli C, Torres T, Romita P, Stingeni L, Hansel K, Mastorino L, Ortoncelli M, Panzone M, Cruz MJ, Bianchi L, Zangrilli A, Musumeci ML, Micali G, Gerbino C, Simonetti O, De Simoni E, Longo C, Mahé E, Di Lernia V
Psoriasis: Targets and Therapy 2025, 15:233-241
Published Date: 28 June 2025
Evolution of Drug Supply for Psoriasis from 2010 to 2022 – Real-World Claims Data Analysis in Germany
Hagenström K, Klinger T, Stephan B, Augustin M
Psoriasis: Targets and Therapy 2025, 15:221-231
Published Date: 27 June 2025
Acupoint Injection Combined with BCG-PSN and Thymosin Enteric-Coated Tablets Improve China Han Psoriasis Vulgaris by Regulating T Cell Subsets
Li J, Zhao X, Pan H, Duan Y, Li W, Zhao Y, Yao L, Zhang K
Psoriasis: Targets and Therapy 2025, 15:209-220
Published Date: 19 June 2025
Are Systemic Drug Choices for Psoriasis by Dermatologists Compatible with Psoriatic Arthritis? Data from the German National Psoriasis Registry PsoBest
Sorbe C, Kargin S, von Kiedrowski R, Thaci D, Weyergraf A, Blome C, Augustin M, Stephan B
Psoriasis: Targets and Therapy 2025, 15:197-207
Published Date: 30 May 2025
Pediatric Pustular Psoriasis in Southern China: A 12-Year Retrospective Analysis of 41 Cases Focusing on Clinical Characteristics and Treatment Outcomes
Tang J, Hou Z, Liao W, Wang Y, Zhang G, Luo Y, Gao X, Wei Z
Psoriasis: Targets and Therapy 2025, 15:185-195
Published Date: 12 May 2025
Challenges Psoriasis and Its Impact on Quality of Life: Challenges in Treatment and Management
Ponikowska M, Vellone E, Czapla M, Uchmanowicz I
Psoriasis: Targets and Therapy 2025, 15:175-183
Published Date: 1 May 2025
Predictors of Quality of Life in Psoriasis Patients: Insights from a Cross-Sectional Study
Walniczek P, Ponikowska M, Kolarczyk EB, Spaleniak P, Mróz-Kijowska K, Czapla M, Uchmanowicz I
Psoriasis: Targets and Therapy 2025, 15:163-174
Published Date: 24 April 2025
Dual Biologic Therapy for Psoriasis in a Patient with Atopic Dermatitis
Ma L, Chen X, Aziz MAA, Chen A, Cai T, Chen S
Psoriasis: Targets and Therapy 2025, 15:159-161
Published Date: 23 April 2025
Real-World Experience of Bimekizumab in a Cohort of 109 Patients Over 48 Weeks and Identification of Predictive Factors for an Early Super Response and Risk of Adverse Events
Fratton Z, Bighetti S, Bettolini L, Maione V, Arisi M, Buligan C, Stinco G, Errichetti E
Psoriasis: Targets and Therapy 2025, 15:145-158
Published Date: 11 April 2025
Infection Risk and Vaccination in the Management of Psoriasis: Considerations for Biologic Therapy
Mateu-Arrom L, Puig L
Psoriasis: Targets and Therapy 2025, 15:127-144
Published Date: 11 April 2025
Psoriasis: Prevalence, Clinical Variants and Quality of Life, Among Patients Attending the Skin Clinic at Mbarara Regional Referral Hospital, Uganda
Lubwama H, Mulyowa GK, Mirembe SK, Katungi TJ, Male M
Psoriasis: Targets and Therapy 2025, 15:117-126
Published Date: 2 April 2025
Analysis of the Reduction in the Duration of Sick Leave for 32,512 Psoriasis Patients Following the Integration of Targeted Therapies for Psoriatic Disease into the Brazilian Healthcare System: a Retrospective Cohort Study
D’Almeida LFV, Duarte GV, Godinho MP, Cariello LH, Sousa GJB, Gomes CM
Psoriasis: Targets and Therapy 2025, 15:105-116
Published Date: 28 March 2025
Treatment With Schistosoma Japonicum Peptide SJMHE1 and SJMHE1-Loaded Hydrogel for the Mitigation of Psoriasis
Liu X, Wang S, Jiang Y, Luo X, Yang Y, Huo L, Ye J, Zhou Y, Yang Z, Du F, Dong L, Mao C, Wang X
Psoriasis: Targets and Therapy 2025, 15:85-104
Published Date: 27 March 2025
Treatment of Psoriasis with II-17 Inhibitors: Comparison of Long-Term Effectiveness and Drug Survival of Secukinumab vs Ixekizumab in Real-World Practice
Lam J, Cazzaniga S, Seyed Jafari SM, Maul JT, Feldmeyer L, Bossart S, Yawalkar N, Heidemeyer K
Psoriasis: Targets and Therapy 2025, 15:71-84
Published Date: 27 March 2025
Acrodermatitis Continua of Hallopeau and Generalised Pustular Psoriasis: Case Reports of Two Different Manifestations of IL36RN Mutation in Siblings
Gu M, Huang H, Xiao Z, Meng F, Sheng H, Lin Z, Li C, Wu Y
Psoriasis: Targets and Therapy 2025, 15:67-70
Published Date: 26 March 2025
A Randomized Controlled Trial for the Optimal Implementation of Psoriasis Treatment by Integrating Chinese and Western Medicine
Yu Y, Sun X, Hu R, Xia P, Wei Y, Yang W, Huang N, Ding Y, Guo S, Yang C, Weng H, Zhang Y, Ding X, Huang Q, Zhou X, Li X, Li B
Psoriasis: Targets and Therapy 2025, 15:55-66
Published Date: 21 March 2025
Metagenomics Analysis of Altered Gut Microbiome in Psoriasis and the Mediation Analysis: A Case-Control Study
Xiao Y, Jing D, Xiao H, Mao M, Kuang Y, Shen M, Lv C, Jian X, Peng C, Chen X
Psoriasis: Targets and Therapy 2025, 15:45-54
Published Date: 19 March 2025
Baseline Pathological Liver Function Tests in Patients With Psoriasis Support the Indication for Systemic Therapy Rather Than Being a Reason Against It: A Real-World Analysis
Krefting F, Scheib C, Benson S, Hölsken S, Placke JM, Wedemeyer H, Sondermann W
Psoriasis: Targets and Therapy 2025, 15:29-44
Published Date: 1 March 2025
Successful Treatment of Linear Psoriasis With the IL-17a-Antagonist Ixekizumab: A Case Report
Christov S, Ohm F, Augustin M, Wagner JN
Psoriasis: Targets and Therapy 2025, 15:23-28
Published Date: 21 January 2025
Shaping Treatment Expectation to Optimize Efficacy of Interleukin 17A Antagonist Secukinumab in Psoriasis Patients
Hölsken S, Krefting F, Mühlhaus S, Bese D, Schedlowski M, Sondermann W
Psoriasis: Targets and Therapy 2025, 15:9-22
Published Date: 10 January 2025
Breakthrough Psoriasis in Patients Receiving Biologicals
Damsin T, Absil G, Libon F, Tassoudji N, Nikkels AF
Psoriasis: Targets and Therapy 2025, 15:1-8
Published Date: 3 January 2025